太极集团：司美格鲁肽注射液药物临床试验批准

Core Viewpoint - Taiji Group's wholly-owned subsidiary, Taiji Group Chongqing Fuling Pharmaceutical Factory, has received approval from the National Medical Products Administration for the clinical trial of Semaglutide injection for type 2 diabetes, indicating progress in the company's drug development pipeline [1] Group 1 - The clinical trial application for Semaglutide injection was accepted on July 4, 2025, and meets the requirements for drug registration [1] - The company has invested approximately RMB 44.1834 million in the research and development of this project to date [1]